In addition, the finding that proliferation in tissue samples was lower when treated with metformin has also been confirmed in women with human epidermal growth factor receptor-2 (HER2)-positive ductal carcinoma in situ [21]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.